Clinical Characteristics and Prognosis of HER2 Gene Phenotype in Patients with Non-Small Cell Lung Cancer

Wei-Ying Diao,1,* Cheng-Long Ding,1,* Bo-Yang Yuan,2 Zan Li,3 Na Sun,4 Jia-Bin Huang5 1Department of Pathology, The First Affiliated Hospital of Jiamusi University, Jimusi City, Heilongjiang Province, 154002, People’s Republic of China; 2Department of Acupuncture and Moxibustion, The...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Diao WY, Ding CL, Yuan BY, Li Z, Sun N, Huang JB
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2021
Materias:
Acceso en línea:https://doaj.org/article/a5d049127c6d4492b1eadf25a058b1bd
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:a5d049127c6d4492b1eadf25a058b1bd
record_format dspace
spelling oai:doaj.org-article:a5d049127c6d4492b1eadf25a058b1bd2021-11-30T18:50:36ZClinical Characteristics and Prognosis of HER2 Gene Phenotype in Patients with Non-Small Cell Lung Cancer1178-7074https://doaj.org/article/a5d049127c6d4492b1eadf25a058b1bd2021-12-01T00:00:00Zhttps://www.dovepress.com/clinical-characteristics-and-prognosis-of-her2-gene-phenotype-in-patie-peer-reviewed-fulltext-article-IJGMhttps://doaj.org/toc/1178-7074Wei-Ying Diao,1,&ast; Cheng-Long Ding,1,&ast; Bo-Yang Yuan,2 Zan Li,3 Na Sun,4 Jia-Bin Huang5 1Department of Pathology, The First Affiliated Hospital of Jiamusi University, Jimusi City, Heilongjiang Province, 154002, People’s Republic of China; 2Department of Acupuncture and Moxibustion, The First Affiliated Hospital of Jiamusi University, Jimusi City, Heilongjiang Province, 154002, People’s Republic of China; 3Department of Analytical Chemistry Teaching and Research, Jiamusi University, Jiamusi City, Heilongjiang Province, 154002, People’s Republic of China; 4Graduate Department, Jiamusi University, Jiamusi, Heilongjiang Province, 154002, People’s Republic of China; 5Department of Geratology, The First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang Province, 154002, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Jia-Bin Huang Email jiadupinglu54972@163.comIntroduction: We aim to investigate the relationship between HER2 gene phenotype and clinical characteristics, distribution and prognosis of non-small cell lung cancer (NSCLC) patients.Methods: A total of 249 NSCLC patients admitted to the oncology department of our hospital from January 2015 to January 2018 were retrospectively analyzed. The clinicopathological information, CT signs, clinical efficacy and long-term prognosis were collected and compared.Results: A total of 249 NSCLC patients underwent HER2 gene testing, 21 of them (8.43%) complied with HER2 alterations [HER2 (+)], and there were significant differences in tumor stages among patients with different HER2 phenotypes (P< 0.05). Among 21 NSCLC patients with HER2 (+), HER2 gene mutation was found in 17 patients (81%), and HER2 gene amplification in 4 patients (19%). Among the HER2 mutations, 12 cases (57%) were 20 exon mutations, and 5 cases (19%) were other mutations. Analysis of CT signs showed that border lobulation/burr, necrosis sign and pleural depression were correlated with HER2 gene mutation (P< 0.05). The incidence of EGRF mutation in HER (+) patients was significantly lower than that in HER (-) patients (P< 0.05), but there was no significant difference in the incidence of ALK gene mutation among different HER phenotypes (P> 0.05). The disease control rate of HER2 (+) patients was significantly lower than that of HER2 (-) patients, and the 12-month progression-free survival rate and survival rate of HER2 (+) patients were significantly higher than those of HER2 (-) patients (P< 0.05). There was no significant difference in the incidence of ADR among HER2 patients with different phenotypes, but the incidence of ADR (adverse drug reaction) in HER2 (+) patients with Grade 3 or 4 was significantly higher than that in the control group (P< 0.05).Discussion: The incidence of HER2 gene mutations in NSCLC patients is relatively low, but it is far commoner in patients with stage IIIB∼IV, among which exon 20 mutations are the most prevalent. In CT signs, the lesion lobulated sign/spiculated sign, necrosis signs, and pleural depression signs are related to HER2 gene mutations. In addition, HER2 gene mutations play a crucial role in the clinical prognosis and treatment safety of patients.Keywords: non-small cell lung cancer, HER2 genotype, CT signs, afatinibDiao WYDing CLYuan BYLi ZSun NHuang JBDove Medical Pressarticlenon-small cell lung cancerher2 genotypect signsafatinibMedicine (General)R5-920ENInternational Journal of General Medicine, Vol Volume 14, Pp 9153-9161 (2021)
institution DOAJ
collection DOAJ
language EN
topic non-small cell lung cancer
her2 genotype
ct signs
afatinib
Medicine (General)
R5-920
spellingShingle non-small cell lung cancer
her2 genotype
ct signs
afatinib
Medicine (General)
R5-920
Diao WY
Ding CL
Yuan BY
Li Z
Sun N
Huang JB
Clinical Characteristics and Prognosis of HER2 Gene Phenotype in Patients with Non-Small Cell Lung Cancer
description Wei-Ying Diao,1,&ast; Cheng-Long Ding,1,&ast; Bo-Yang Yuan,2 Zan Li,3 Na Sun,4 Jia-Bin Huang5 1Department of Pathology, The First Affiliated Hospital of Jiamusi University, Jimusi City, Heilongjiang Province, 154002, People’s Republic of China; 2Department of Acupuncture and Moxibustion, The First Affiliated Hospital of Jiamusi University, Jimusi City, Heilongjiang Province, 154002, People’s Republic of China; 3Department of Analytical Chemistry Teaching and Research, Jiamusi University, Jiamusi City, Heilongjiang Province, 154002, People’s Republic of China; 4Graduate Department, Jiamusi University, Jiamusi, Heilongjiang Province, 154002, People’s Republic of China; 5Department of Geratology, The First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang Province, 154002, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Jia-Bin Huang Email jiadupinglu54972@163.comIntroduction: We aim to investigate the relationship between HER2 gene phenotype and clinical characteristics, distribution and prognosis of non-small cell lung cancer (NSCLC) patients.Methods: A total of 249 NSCLC patients admitted to the oncology department of our hospital from January 2015 to January 2018 were retrospectively analyzed. The clinicopathological information, CT signs, clinical efficacy and long-term prognosis were collected and compared.Results: A total of 249 NSCLC patients underwent HER2 gene testing, 21 of them (8.43%) complied with HER2 alterations [HER2 (+)], and there were significant differences in tumor stages among patients with different HER2 phenotypes (P< 0.05). Among 21 NSCLC patients with HER2 (+), HER2 gene mutation was found in 17 patients (81%), and HER2 gene amplification in 4 patients (19%). Among the HER2 mutations, 12 cases (57%) were 20 exon mutations, and 5 cases (19%) were other mutations. Analysis of CT signs showed that border lobulation/burr, necrosis sign and pleural depression were correlated with HER2 gene mutation (P< 0.05). The incidence of EGRF mutation in HER (+) patients was significantly lower than that in HER (-) patients (P< 0.05), but there was no significant difference in the incidence of ALK gene mutation among different HER phenotypes (P> 0.05). The disease control rate of HER2 (+) patients was significantly lower than that of HER2 (-) patients, and the 12-month progression-free survival rate and survival rate of HER2 (+) patients were significantly higher than those of HER2 (-) patients (P< 0.05). There was no significant difference in the incidence of ADR among HER2 patients with different phenotypes, but the incidence of ADR (adverse drug reaction) in HER2 (+) patients with Grade 3 or 4 was significantly higher than that in the control group (P< 0.05).Discussion: The incidence of HER2 gene mutations in NSCLC patients is relatively low, but it is far commoner in patients with stage IIIB∼IV, among which exon 20 mutations are the most prevalent. In CT signs, the lesion lobulated sign/spiculated sign, necrosis signs, and pleural depression signs are related to HER2 gene mutations. In addition, HER2 gene mutations play a crucial role in the clinical prognosis and treatment safety of patients.Keywords: non-small cell lung cancer, HER2 genotype, CT signs, afatinib
format article
author Diao WY
Ding CL
Yuan BY
Li Z
Sun N
Huang JB
author_facet Diao WY
Ding CL
Yuan BY
Li Z
Sun N
Huang JB
author_sort Diao WY
title Clinical Characteristics and Prognosis of HER2 Gene Phenotype in Patients with Non-Small Cell Lung Cancer
title_short Clinical Characteristics and Prognosis of HER2 Gene Phenotype in Patients with Non-Small Cell Lung Cancer
title_full Clinical Characteristics and Prognosis of HER2 Gene Phenotype in Patients with Non-Small Cell Lung Cancer
title_fullStr Clinical Characteristics and Prognosis of HER2 Gene Phenotype in Patients with Non-Small Cell Lung Cancer
title_full_unstemmed Clinical Characteristics and Prognosis of HER2 Gene Phenotype in Patients with Non-Small Cell Lung Cancer
title_sort clinical characteristics and prognosis of her2 gene phenotype in patients with non-small cell lung cancer
publisher Dove Medical Press
publishDate 2021
url https://doaj.org/article/a5d049127c6d4492b1eadf25a058b1bd
work_keys_str_mv AT diaowy clinicalcharacteristicsandprognosisofher2genephenotypeinpatientswithnonsmallcelllungcancer
AT dingcl clinicalcharacteristicsandprognosisofher2genephenotypeinpatientswithnonsmallcelllungcancer
AT yuanby clinicalcharacteristicsandprognosisofher2genephenotypeinpatientswithnonsmallcelllungcancer
AT liz clinicalcharacteristicsandprognosisofher2genephenotypeinpatientswithnonsmallcelllungcancer
AT sunn clinicalcharacteristicsandprognosisofher2genephenotypeinpatientswithnonsmallcelllungcancer
AT huangjb clinicalcharacteristicsandprognosisofher2genephenotypeinpatientswithnonsmallcelllungcancer
_version_ 1718406344008007680